ACTIVE Articular Cartilage Treatment with Injectable hydrogel is Valuable and long-term Effective
- Coordinator
- Hy2care BV, Netherlands
- Runs
- 1 October 2022 to 30 September 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €3.7m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190135342
What the project is doing
In the project's own words, from its summary on CORDIS.
Hy2Care brings a regenerative Injectable Hydrogel, of joint- and cartilage-mimicking composition, that is used to treat damaged cartilage. The cartilage defects are easily filled with a syringe during a standard one time arthroscopy. The hydrogel fill the defect, prevents ingrowth of scar tissue and allows the body to heal itself by creating true Hyaline cartilage, ensuring an optimal regenerated tissue. The high-quality regeneration provides the basis for a long lasting repair, postponing or even preventing the onset of osteoarthritis.
The gel binds covalently to the surrounding cartilage ensuring integration of the new tissue. Revalidation is fast as the cartilage regrowth follows the degradation of the gel. The lasting repair not only prevents additional secondary treatments but also pain, disability and escalating follow-on costs. In submission of the last cut off of the EIC in october 2020 Hy2Care scored a 14.0 and recieved the seal of excellence.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Hy2care BV | Geleen | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI